One instance of this involves targeting metabolic processes, such as the TCA cycle, in anti-tumor immune cells, including cytotoxic CD8 + T cells and effector CD4 + T cells, to maintain their effectiveness. The gene discussed is CD8A; the disease is neoplasm.